Systemic Therapy in Urothelial Carcinoma

Sarmad Sadeghi, MD, PhD


Department of Medicine

Institute of Urology

University of Southern California

August 24, 2024

Current Standard of Care for UC




The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer


H. Barton Grossman, M.D., Ronald B. Natale, M.D., Catherine M. Tangen, Dr.P.H.,
V.O. Speights, D.O., Nicholas J. Vogelzang, M.D., Donald L. Trump, M.D.,
Ralph W. deVere White, M.D., Michael F. Sarosdy, M.D., David P. Wood, Jr., M.D.,
Derek Raghavan, M.D., Ph.D., and E. David Crawford, M.D.

N ENGLJMED 349;9 WWW.NEJM.ORG AUGUST 28, 2003



(M-VAC) Followed by Cystectomy or Cystectomy Alone, According to an Intention-to-Treat Analysis.

N ENGL J MED 349;9 WWW.NEJM.ORG AUGUST 28, 2003



N ENGLJ MED 349;9 WWW.NEJM.ORG AUGUST 28, 2003

Frontline Chemotherapy

Long Term Results: GC vs MVAC Von der Maase JCO 2005





Fig 1. Kaplan-Meier curves for overall survival. GC, gemcitabine/cisplatin; MVAC, methotrexate/vinblastine/doxorubicin/cisplatin; HR, hazard ratio; Pts, patients.

Fig 2. Kaplan-Meier curves for progression-free survival. GC, gemcitabine/ cisplatin; MVAC, methotrexate/vinblastine/doxorubicin/cisplatin; HR, hazard ratio; Pts, patients.

Frontline Chemotherapy

ddMVAC vs MVAC Sternberg Eur J Cancer 2006



2) Is one better for select patients?

SWOG S1314: A randomized phase II study of coexpression extrapolation (COXEN) with neoadjuvant chemotherapy for bladder cancer.

Thomas W. Flaig, Catherine M. Tangen, Siamak Daneshmand, Ajjai Shivaram Alva, Seth P. Lerner, M. Scott Lucia, David James McConkey, Dan Theodorescu, Amir Goldkorn, Matthew I. Milowsky, Rick Bangs, Gary R. MacVicar, Bruno R. Bastos, Daniel Gustafson, Melissa Plets, Ian Murchie Thompson Jr.

Division of Medical Oncology, School of Medicine, University of Colorado, Aurora, CO; Fred Hutchinson Cancer Research Center, Seattle, WA; Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA; University of Michigan, Ann Arbor, MI; Baylor College of Medicine, Houston, TX; University of Colorado Anschutz Medical Campus, Aurora, CO; Johns Hopkins School of Medicine, Baltimore, MD; Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, Los Angeles, CA; Division of Medical Oncology, Department of Medicine, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA; University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC; SWOG, San Antonio, TX; Illinois CancerCare PC, Peoria, IL; Cleveland Clinic Florida, Weston, FL; Colorado State University, Fort Collins, CO; CHRISTUS Medical Center Hospital, San Antonio, TX





S1314: Descriptive data on pathologic response by treatment arm in evaluable subjects

N=167	GC (N=82)	ddMVAC (N=85)	Total Randomized: N=237	
Chemotherapy Response			Ineligible: N=9	I
CR (рТ0)	28 (35%)	27 (32%)	Eligible: N=228	
PR (downstaged to ≤T1)	12 (15%)	20 (24%)	Received < 3 cycle chemo: N=23	les
CR + PR	40 (50%)	47 (56%)	Did not receive cystectomy withi	nin
Non-responders	42 (50%)	38 (44%)	100 days: N=38 Evaluable: N=167 (GC=82; ddMVAC=85)	8

No statistically significant difference between the two.

Not powered for OS.







MULTICENTER RANDOMIZED PHASE III OF DOSE DENSE MVAC OR GC AS PERIOPERATIVE CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER

Overall Survival at 5 years in the GETUG/AFU V05 VESPER trial

Ch Pfister, G Gravis, A Flechon, C Chevreau, H Mahammedi, B Laguerre, A Guillot,



F Joly, Y Allory, V Harter and S Culine for the Vesper trial investigators



2023 ASCO ANNUAL MEETING #ASCO23 PRESENTED BY: C Pfister - 5-y OS Vesper Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Trial design (1)

Chemotherapy

≻ 4 cycles of GC		ncitabine 1250 mg/m² d1 and d8 Ilatin 70 mg/m² d1	every 3
➢ 6 cycles of ddM	VAC	Methotrexate 30 mg/m ² d1 Vinblastine 3 mg/m ² d2 Doxorubicin 30 mg/m ² d2 Cisplatin 70 mg/m ² d2 <i>+ G-CSF support from d3 to d9</i>	every 2

Trial design (3)

2023 ASCO

#ASCO23

- 500 patients included in 28 centers from 2013 to 2018
 - (493 patients available for intent-to-treat analysis)
- Adjuvant (n=56) and Neoadjuvant (n=437) (88%)
- Primary end-point : Progression Free Survival at 3 years
- Final analysis : Overall and Specific Survival at 5 years

Inclusion criteria

> Pure or mixed urothelial bladder cancer (neuroendocrine excluded)


2021 SVOCONGRESS

- ECOG PS < 2 and all criteria for cisplatin eligibility</p>
- Written informed consent

AND

- \geq T2, N0 (*LN* \leq 10 mm on *CT* scan), M0 (Neoadjuvant CT)
- > pT2 or pN+ and M0 (Adjuvant CT)

PFS at 3 years



PRESENTED BY C Pfister - 5-V OS Vesner

Perioperative dd-MVAC improve 3-y PFS over GC

6-21 September 2021

In the neoadjuvant group, better bladder tumor local control with a significant improvement on 3-y PFS in the dd-MVAC arm

Pfister et al. J Clin Oncol 2022

ASCO AMERICAN SOCIETY C

VIEDGE CONQUERS CANCEL

PRESENTED BY: C Pfister - 5-y OS Vesper

ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER 2023 ASCO ANNUAL MEETING #ASCO23

org.


PFS at 3 years

#ASCO23

2023 ASCO

ANNUAL MEETING





Perioperative dd-MVAC improve 3-y PFS over GC

In the neoadjuvant group, better bladder tumor local control with a significant improvement on 3-y PFS in the dd-MVAC arm


Pfister et al. J Clin Oncol 2022

PRESENTED BY: C Pfister - 5-y OS Vesper Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org



Results (1)

Overall Survival at 5 years



2023 ASCO ANNUAL MEETING

#ASCO23

PRESENTED BY: C Pfister - 5-y OS Vesper

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



Conclusions/Take-Home Messages

- Vesper trial is a milestone in the history of CT for MIBC
- The study did NOT meet its primary endpoint:
 PFS 3-year rate: 64% v 56%, hazard ratio [HR] = 0.77 [95% CI, 0.57 to 1.02], P = .066- JCO 2022

ypT0N0 42% vs 36%, p=0.2

#ASCO23

0

0

No OS 5-year rate benefit in the overall group. But

overall survival at 5 years was improved in the neoadjuvant dd-MVAC group versus the GC group (66% [95% CI 60-73]vs 57% [50-64], HR 0·71 [95% CI 0·52-0·97])

40% in neoadjuvant and 60% in adjuvant setting could not get 6 cycles

PRESENTED BY: C Pfister - 5-y OS Vesper Presentation is property of the author and ASCO. Permission required for reuse: contact permissions@asco.org.



PURE-01 (NCT02736266): Neoadjuvant pembrolizumab before radical cystectomy for MIBC

- Fit and planned for cystectomy
- Predominant (i.e. 50% at least) UC histology
- cT≤3bN0 stage
- Residual disease after TURB (surgical opinion, cystoscopy or radiological presence)
- GFR ≥20 ml/min (Cockcroft Gault formula)
- ECOG-PS 0-1

3×3 weekly cycles of pembrolizumab 200 mg IV

Pre-post treatment tissue/blood sample collection for biomarker analyses

Pre-post treatment imaging: multiparametric bladder MRI (mpMRI); ¹⁸FDG-PET/CT scan, T/A CT scan

Additional DD-MVAC x 4 cycles in nonresponding pts (investigator choice)

Cystectomy

- Post-cystectomy management according to EAU guidelines
- Survival data collected until 2-y post cystectomy

- Pathologic complete response (pT0) in ITT population is the primary endpoint
- The H₁ is pT0 \geq 25% and H₀ pT0 \leq 15%
- 71 pts will be enrolled, with 43 pts at first stage according to MinMax design
- pT0 limits for H0 rejection: 6 (1st stage); 14 (2nd stage)
- 80% power and a one-sided test of significance at the 10% level
- Data cut-off: May 10th, 2018: Median Follow-up: 8 months

PRESENTED AT: 2018 ASCO ANNUAL MEETING #ASCO18 Slides are the property of the author permission required for reuse.

PRESENTED BY: ANDREA NECCHI

Presented By Andrea Necchi at 2018 ASCO Annual Meeting

Results (1)

Ρ

Τa

in


Va

Cli

Se

Pa

Overall Survival at 5 years



2023 ASCO

#ASCO23

PRESENTED BY: C Pfister - 5-y OS Vesper

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org



PURE-01


 Table 2.
 Univariable and multivariable Cox regression models predicting EFS.

	Univariable ana	lyses	Multivariable analyses		
Variable	HR (95%CI)	P ^a	HR (95%CI)	Pa	
Age (continuous)	1.00 (0.97-1.04)	0.6	_	_	
Sex (Male vs. Female)	1.15 (0.44–3.00)	0.8	_	_	
Previous NMIBC	0.76 (0.17-3.33)	0.7	_	_	
Previous BCG	0.72 (0.12-4.20)	0.7	_	_	
Histology:					
Pure UC (ref.)					
 Non-predominant VH (ref.) 	2.51 (0.91-6.92)	0.07	_	_	
Predominant VH	0.76 (0.28-2.06)	0.6	_	_	
TMB (Mut/Mb; continuous)	0.95 (0.90-1.00)	0.09	0.95 (0.91-1.00)	0.1	
CPS (%; continuous)	0.96 (0.95–0.98)	0.001	0.97 (0.95-0.99)	0.003	
Clinical T-stage:					
• cT2N0 (ref.)					
• cT3-4N0	2.50 (1.20-5.17)	0.01	2.20 (1.09-4.45)	0.03	

Abbreviations: BCG, Bacillus Calmette-Guérin; CPS, combined positive score; HR, hazard ratio; NMIBC, non-muscle-invasive bladder cancer; ref., reference group; TMB, tumor mutational burden; UC, urothelial carcinoma; VH, variant histology.

^aTwo-sided Wald test *P* value.

Is the addition of chemotherapy to immunotherapy necessary?



2022 ASCO ANNUAL MEETING


#ASC022

PRESENTED BY: Matthew Milowsky, MD

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.



Is the addition of immunotherapy to chemotherapy necessary?





#ASC022

PRESENTED BY: Matthew Milowsky, MD

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.



What endpoints should be used for neoadjuvant trials in bladder cancer?

- pCR individual-level and trial-level surrogacy for time-to-event endpoints (EFS, DFS, OS) is not clear in MIBC
 - Magnitude of pathologic response improvement that translates into meaningful clinical benefit?
- pCR may be used to guide subsequent therapy on a trial level i.e., more therapy for those without pCR (used in breast cancer and c/w CheckMate 274 and more to come related to ctDNA)
- Current trials must have "highly granular patient-related, tumor-related and treatment-related characteristics" to inform design of future trials

Nat Rev Urol. 2022 Jan;19(1):37-46.



PRESENTED BY: Matthew Milowsky, MD

Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.




26

CheckMate 274: Adjuvant Nivolumab vs Placebo After Radical Surgery ± Neoadjuvant CT in High-Risk MIUC

First analysis of international, randomized, double-blind phase III trial

Stratified by PD-L1 status (< vs ≥ 1%*), previous neoadjuvant cisplatin-based CT, nodal status

Patients with high-risk MIUC; if ypT2-ypT4a or ypN+, received neoadjuvant cisplatin CT; if pT3-pT4a or pN+, did not receive neoadjuvant cisplatin CT and ineligible for/refused adjuvant cisplatin CT; underwent radical surgery ≤ 120 days; disease free within 4 wks of study dosing (N = 709)



Primary endpoints: DFS is ITT population, DFS in all randomized patients with PD-L1 ≥ 1%

*Per PD-L1 IHC 28-8 PharmDx assay. [†]OS data immature at time of analysis.

Bajorin. ASCO GU 2021. Abstr 391. NCT02632409.

- Secondary endpoints: nonurothelial tract recurrence-free survival, disease-specific survival, OS[†]
- Exploratory endpoints: distant metastasis– free survival, safety, HRQoL
 Slide credit: clinicaloptions.com

Subgroup	No. of Patients	Nivolumab	Placebo	Hazard Ratio for Disease Recurrence	or Death (95% CI)
		no. of events/r	no. of patients		
All patients	709	170/353	204/356		0.70 (0.57-0.86)
Initial tumor origin					
Urinary bladder	560	129/279	166/281	_	0.62 (0.49-0.78)
Renal pelvis	96	24/44	25/52		1.23 (0.67–2.23)
Ureter	53	17/30	13/23	?	1.56 (0.70–3.48)
Minor histologic variants					
Yes	286	70/145	76/141		0.73 (0.53-1.02)
No	423	100/208	128/215	¦	0.69 (0.53–0.90)
Nodal status			,	1	
N+	335	95/167	116/168	i	0.64 (0.48-0.85)
N0 or NX with <10 nodes removed	193	46/94	50/99	•	0.85 (0.57–1.28)
N0 with ≥10 nodes removed	179	29/91	37/88		0.67 (0.41–1.10)
Not reported	2	0/1	1/1	1	`NA ´
Pathological tumor stage		,	,		
pT0-2	166	35/80	40/86	•	0.88 (0.54-1.43)
pT3	410	97/206	120/204	_ _	0.63 (0.48–0.82)
pT4a	119	36/57	40/62	<u>_</u>	0.77 (0.47–1.25)
Other	12	1/9	3/3		`NA ´
Not reported	2	1/1	1/1	1	NA
Pathological tumor stage and nodal statu	S	,	,		
pT2N-	54	6/25	10/29		0.54 (0.16-1.86)
pT3,4N-	317	68/158	78/159		0.75 (0.54–1.05)
pT0-4N1	143	39/71	45/72	•	0.74 (0.47–1.15)
pT0-4N2,3	192	56/96	71/96	¦	0.57 (0.40–0.83)
pTisN-	1	0/1	Ó	1	`NA ´
Not reported	2	1/2	0		NA
Previous neoadjuvant cisplatin therapy		,		1	
Yes	308	70/153	100/155	¦	0.52 (0.38-0.71)
Νο	401	100/200	104/201	<u>_</u>	0.92 (0.69–1.21)
Any previous neoadjuvant systemic thera	ру	,			. /
Ýes	319	75/160	104/159	_ _	0.53 (0.39-0.72)
No	390	95/193	100/197		0.91 (0.69–1.21)
Not reported	2	0/1	1/1		` NA Ú
		'	,		
				0.25 0.50 1.00 2.00 4.00	
				← →	
				Nivolumah Better Diacebo Better	

Nivolumab Better Placebo Better

Subgroup	No. of Patients	Nivolumab no. of events/r	Placebo	Hazard Ratio for Disease Recurrence of	or Death (95%)
All patients	709	170/353	204/356	_ —	0.70 (0.57–0.
Age		2	-		-
<65 yr	291	74/155	70/136		0.77 (0.55–1.
≥65 yr and <75 yr	295	64/131	100/164	i	0.68 (0.49–0.
≥75 yr	123	32/67	34/56		0.63 (0.38–1.
Sex					
Male	540	125/265	156/275		0.68 (0.54–0.
Female	169	45/88	48/81		0.76 (0.50–1.
Previous neoadjuvant cisplatin therapy				i	
Yes	308	70/153	100/155	_ -	0.52 (0.38-0.
No	401	100/200	104/201	—• ; ??	0.92 (0.69–1.
Any previous neoadjuvant systemic therap				1	
Yes	319	75/160	104/159		0.53 (0.39–0.
No	390	95/193	100/197		<u>0.91 (0.69–1.</u>
Days from surgery to randomization	_	• •			
0-30	5	0/2	2/3		NA
>30-60	149	43/79	40/70		0.66 (0.40-1
>60–90	342	78/165	93/177	÷	0.76 (0.55–1.
>90-120	198	47/103	62/95	;	0.67 (0.44–1
>120	15	2/4	7/11	1	NA
Smoking status					
Current or former smoker	484	116/237	141/247		0.70 (0.55–0.
Never smoked	215	53/111	61/104	¦	0.67 (0.45–0.
Unknown	10	1/5	2/5	1	` NA
PD-L1 expression level at baseline					
≥1%	280	55/139	79/141	i	0.56 (0.40–0.
<1%	419	114/210	120/209		0.82 (0.63–1.
Indeterminate or not able to be evaluate	d 8 2	1/3	4/5		NA
Not reported	2	0/1	1/1	· · · · · · · · · · · · · · · · · · ·	NA
				0.25 0.50 1.00 2.00 4.00	
				0.25 0.50 1.00 2.00 4.00	
				Nivolumab Better Placebo Better	
				NIVOLUIILAD DELLEI FIACEDO DELLEI	
	12	1/5	- 1 - 1		

CheckMate 274: Efficacy Outcomes


	п	п	PD-L1	≥ 1%	
Median, Mos	NivolumabPlacebo(n = 353)(n = 356)		Nivolumab (n = 140)	Placebo (n = 142)	
DFS (primary endpoints)	21.0	10.9	NR	10.8	
HR for DFS	0.70 (98.31% Cl: 0	.54-0.89); <i>P</i> < .001	0.53 (98.87% CI: 0.34-0.84); <i>P</i> < .001		
NUTRFS	24.6	13.7	NR	10.9	
HR for NUTRFS	0.72 (95% C	I: 0.58-0.89)	0.54 (95% CI: 0.38-0.77)		
DMFS	35.0	29.0	NR	21.2	
HR for DMFS	0.74 (95% C	I: 0.58-0.93)	0.60 (95% C	l: 0.41-0.88)	

- Study met its primary endpoints: nivolumab significantly prolonged DFS vs placebo in the ITT population and patients with PD-L1 ≥ 1% (both P < .001)</p>
- Nivolumab prolonged DFS vs placebo in most subgroups of ITT population except for patients with initial tumor origin in renal pelvis (HR: 1.16; 95% CI: 0.63-2.13) and ureter (HR: 1.55; 95% CI: 0.70-3.45)

Bajorin. ASCO GU 2021. Abstr 391.

Upper Tract: Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial

Alison Jane Birtle, MD, MBBS, MRCP, FRCR^{1,2,3} (D); Robert Jones, PhD, MBChB^{4,5} (D); John Chester, PhD, MRCP, MBBS⁶ (D); Rebecca Lewis, BSc⁷ (D);





EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma


<u>Thomas Powles</u>, Begona Perez-Valderrama, Shilpa Gupta, Jens Bedke, Eiji Kikuchi, Jean Hoffman-Censits, Gopa Iyer, Christof Vulsteke, Se Hoon Park, Sang Joon Shin, Daniel Castellano Gauna, Giuseppe Fornarini, Jian-Ri Li, Mahmut Gumus, Nataliya Mar, Sujata Narayanan, Xuesong Yu, Seema Gorla, Blanca Homet Moreno, Michiel Van der Heijden



FPN: LBA6

RATIONALE FOR COMBINING ENFORTUMAB VEDOTIN + PEMBROLIZUMAB

<u>ADCs¹</u> linked to monomethyl auristatin E (MMAE) induce immunogenic cell death (ICD) in preclinical and in vitro data, and may enhance anti-tumor immunity



 <u>MMAE</u> disrupts microtubules resulting in ICD due to ER stress


 ICD releases innate immuneactivating molecules resulting in APC activation and presentation of tumor antigens to T cells

 <u>T cells</u> mount antigen-specific response augmented by PD-1/L1 inhibitors

Antibody drug conjugates are investigational agents, and their safety and efficacy have not been established. ©2019 Seattle Genetics, Inc.

¹ Brentuximab vedotin, ladiratuzumab vedotin, and tisotumab vedotin. References: Cao et al. AACR 2016. Cao et al. Cancer Res 2017;77(13 suppl): Abstract 5588. Cao et al. Cancer Res 2018;78(13 Suppl): Abstract 2742. Alley et al. Cancer Res 2019;79(13 Suppl): Abstract 221.

EV-302/KEYNOTE-A39 (NCT04223856)



Stratification factors: cisplatin eligibility (eligible/ineligible), PD-L1 expression (high/low), liver metastases (present/absent)

Cisplatin eligibility and assignment/dosing of cisplatin vs carboplatin were protocol-defined; patients received 3-week cycles of EV (1.25 mg/kg; IV) on Days 1 and 8 and P (200 mg; IV) on Day 1

Statistical plan for analysis: the first planned analysis was performed after approximately 526 PFS (final) and 356 OS events (interim); if OS was positive at interim, the OS interim analysis was considered final

BICR, blinded independent central review; ECOG PS, Eastern Cooperative Oncology Group performance status; GFR, glomerular fil tration rate; ORR, overall response rate; PFS, progression-free survival; R, randomization; RECIST, Response Evaluation Criteria in SolidTumors ^aMeasured by the Cockcroft-Gault formula, Modification of Diet in Renal Disease, or 24-hour urine ^bPatients with ECOG PS of 2 were required to also meet the additional criteria: hemoglobin ≥10 g/dL, GFR ≥50mL/min, may not have NYHA class III heart failure ^cMaintenance therapy could be used following completion and/or discontinuation of platinum-containing therapy

Data cutoff: 08 Aug 2023; FPI: 7 Apr 2020, LPI: 09 Nov 2022



Overall Survival

Risk of death was reduced by 53% in patients who received EV+P


Subgroup	EV+P	Chemotherapy	Hazard Ratio (95% CI)		
Overall	223/442	307/444	⊢_ ∎]	0.45 (0.38-0.54)	
Age)
<65 years	75/144	88/135	⊢	0.45 (0.32-0.62)	3)
≥65 years	148/298	219/309	<u>⊢∎</u> _{	0.45 (0.36-0.56)	~/
Sex					ont
Female	55/98	74/108		0.49 (0.34-0.71)	
Male	168/344	233/336		0.44 (0.36-0.54)	
ECOG PS					
0	93/223	146/215		0.36 (0.28-0.48)	
1-2	130/219	161/227	⊢ ∎−−1	0.53 (0.42-0.68)	
Primary disease site of origin					
Upper tract	69/135	70/104	⊢−− ∎−−−−4	0.50 (0.35-0.71)	
Lower tract	152/305	236/339	⊢-∎1	0.44 (0.35-0.54)	
Liver metastases					
Present	66/100	78/99		0.53 (0.38-0.76)	
Absent	157/342	229/345	⊢ -∎1	0.43 (0.35-0.52)	
PD-L1 expression					
Low (CPS <10)	105/184	127/185	├── ∎──┤	0.50 (0.38-0.65)	
High (CPS ≥10)	116/254	176/254		0.42 (0.33-0.53)	
Cisplatin eligibility					
Eligible	117/244	149/234		0.48 (0.38-0.62)	
Ineligible	106/198	158/210		0.43 (0.33-0.55)	
			<u> </u>	<u> </u>	
		0.1	1 Fevere EV/LD Fevere shows	5	
			mOS, median overall survival; NR, not reached	omerapy	
00000000					





Confirmed Overall Response per BICR

Significant improvement in objective response rate was observed with EV+P



	EV+P (N=437)	Chemotherapy (N=441)	
Confirmed ORR, n (%) (95% CI)	296 (67.7) (63.1-72.1)	196 (44.4) (39.7-49.2)	
2-sided P value	<0.00001		
Best overall response ^a , n (%)			
Complete response	127 (29.1)	55 (12.5)	
Partial response	169 (38.7)	141 (32.0)	
Stable disease	82 (18.8)	149 (33.8)	
Progressive disease	38 (8.7)	60 (13.6)	
Not evaluable/No assessment ^b	21 (4.8)	36 (8.2)	

CR, complete response; DOR, duration of response; PR, partial response

^aBest overall response according to RECIST v1.1 per BICR. CR or PR was confirmed with repeat scans ≥28 days after initial response ^bPatients had either post-baseline assessment and the best overall response was determined to be not evaluable per RECIST v1.1 or no response assessment post-baseline



EV Treatment-Related Adverse Events of Special Interest*

Majority of treatment-related AESIs were low grade

	EV+P (N=440) n (%)		Chemotherapy (N=433) n (%)	
	Any grade	Grade≥3	Any grade	Grade≥3
Skin reactions	294 (66.8)	68 (15.5)	60 (13.9)	1 (0.2)
Peripheral neuropathy	278 (63.2)	30 (6.8)	53 (12.2)	0 (0.0)
Sensory events	260 (59.1)	19 (4.3)	51 (11.8)	0 (0.0)
Motor events	44 (10.0)	12 (2.7)	5 (1.2)	0 (0.0)
Ocular disorders	94 (21.4)	0 (0.0)	12 (2.8)	0 (0.0)
Dry eye	82 (18.6)	0 (0.0)	8 (1.8)	0 (0.0)
Hyperglycemia	57 (13.0)	27 (6.1)	3 (0.7)	0 (0.0)
Infusion-related reactions	9 (2.0)	0 (0.0)	9 (2.1)	0 (0.0)




*There are differences in the rates of skin reactions reported for EV treatment-related AESIs and P TEAEs of special interest because these adverse events were reported via different methodologies developed for EV and P monotherapies, respectively AESI, adverse event of special interest

Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance




David H. Aggen¹, Carissa E. Chu², and Jonathan E. Rosenberg¹




In Solid Tumors and In Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer

Niklas Klümper, MD^{1,2,3,4} (b); Ngoc Khanh Tran^{1,2,3} (b); Stefanie Zschäbitz, MD⁵; Oliver Hahn, MD⁶ (b); Thomas Büttner, MD^{1,3} (b);

- **MATERIALS** We established a *NECTIN*4-specific fluorescence in situ hybridization (FISH) **AND METHODS** assay to assess the predictive value of *NECTIN*4 CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108). CNVs were correlated with membranous NECTIN4 protein expression, EV treatment responses, and outcomes. We also assessed the prognostic value of *NECTIN*4 CNVs measured in metastatic biopsies of non-EV-treated mUC (mUC-non-EV, n = 103). Furthermore, we queried The Cancer Genome Atlas (TCGA) data sets (10,712 patients across 32 cancer types) for *NECTIN*4 CNVs.
 - **RESULTS** *NECTIN4* amplifications are frequent genomic events in muscle-invasive bladder cancer (TCGA bladder cancer data set: approximately 17%) and mUC (approximately 26% in our mUC cohorts). In mUC-EV, *NECTIN4* amplification represents a stable genomic alteration during metastatic progression and associates with enhanced membranous NECTIN4 protein expression. Ninety-six percent (27 of 28) of patients with *NECTIN4* amplifications demonstrated objective responses to EV compared with 32% (24 of 74) in the nonamplified subgroup (P < .001). In multivariable Cox analysis adjusted for age, sex, and





J Clin Oncol 00:1-10 © 2024 by American Society of Clinical Oncology



Abstract 456262: Association of EphrinB2 (B2) expression with overall survival (OS) and resistance to PD1/L1 inhibitors in metastatic urothelial carcinoma (mUC)



Sarmad Sadeghi¹, Nataliya Mar², Denice Tsao-Wei³, Karam Ashouri³, Imran Siddiqi¹, Jon P Cogan⁴, Alexandra Jackovich⁵, Dory Freeman⁶, Jillian O'Toole⁶, Thomas W. Flaig⁷, Parkash S. Gill¹, Arash Rezazadeh², Guru P. Sonpavde⁸, Joaquim Bellmunt⁶

Background

EphrinB2 is a transmembrane protein expressed in developing arterial capillary endothelium; it is minimally expressed in adults but re-expressed in tumors and tumor blood vessel. Its expression is a poor prognostic marker (TCGA). High EphrinB2 expression in tumor blood vessels functions as a gate-keeper by preventing immune cells in the circulation from migrating into the tumor. The trial of pembrolizumab+sEphB4-HSA (an EphrinB2 inhibitor) in mUC showed a higher response rate in EphrinB2 high patients compared to pembrolizumab historical data- 52% vs 21%- JCO PMID 35984996. This raised the question whether immunotherapy alone could overcome the poor prognostic effect of EphrinB2?

Objectives

This retrospective study was designed to examine the response to immunotherapy monotherapy in patients with mUC and correlate it with EphrinB2 expression.

Methods

Patients with mUC who received a PD1/PDL1 antibody after prior systemic therapy who had tissue available for analysis were eligible. Demographics, disease characteristics, and radiographic response data were also required and collected. In situ hybridization was used to assess the expression EphrinB2 in tumor specimens from 3 participating site: University of Southern California (USC), Dana Farber Cancer Institute (DFCI), and University of California, Irvine (UCI).

EphrinB2 is a biomarker of resistance to PD1/L1 inhibitors in mUC and predicts low response rate and poor overall survival.


EphrinB2 inhibition may overcome the resistance to PD1/PDL1 inhibitors in patients whose tumors express high levels of EphrinB2


The role of EphrinB2 in resistance to immunotherapy merits further investigation.

For questions or comments please contact Sarmad Sadeghi sarmadsa@med.usc.edu

Results	(Contin	uea

PD1/L1 inhibitors included pembrolizumab 78%. atezolizumab 17%, nivolumab, avelumab, and durvalumab in 3, 1, and 1%, respectively.





Conclusion and Future Directions

The role of EphrinB2 in resistance to immunotherapy merits further investigation.

Whether EphrinB2 inhibition also improves outcomes of non-immunotherapy regimens remains unclear.

Results						
	All N=143	USC n=49	DFCI, n=55	UCI, n=39	Р	
Median Age (range)	73 (48-91)	72 (48-87)	73 (48-91)	74 (48-90)	0.82	
Male (%)	101 (71%)	37 (76%)	36 (65%)	28 (72%)	0.53	
ECOG 0, 1, >1 (%)	42, 35, 23	51, 22, 27	40, 40, 21	33, 44, 23	0.23	
Visceral Metastases (%)	79 (55%)	26 (53%)	36 (65%)	17 (44%)	0.11	
Responders (ORR)*	28 (21%)	10 (20%)	11 (20%)	7 (22%)	1	
EphrinB2 Low Cases	55 (40%)	21 (43%)	19 (35%)	15 (47%)		
Responders (ORR)	18 (33%)	6 (29%)	7 (37%)	5 (33%)	0.005	
EphrinB2 High Cases	81 (60%)	28 (57%)	36 (65%)	17 (53%)	0.005	
Responders (ORR)	10 (12%)	4 (14%)	4 (11%)	2 (12%)		
Median OS in months	17.2	16	14.5	32	0.32	
(95% CI)	(13.5, 23.8)	(8.1, 30.1)	(9.0, 18.0)	(13.3, 60.8)	0.52	
EphrinB2 Low Cases	60 (42%)	21 (43%)	19 (35%)	20 (51%)		
Median OS in months	24	24	17.5	45.1		
(95% CI)	(13.7, 60.8)	(9.2, NA)	(7.3, 27.6)	(10.8, 60.8)	0.022	
EphrinB2 High Cases	83 (58%)	28 (57%)	36 (65%)	19 (49%)	0.022	
Median OS in months	14.5	8.8	13.8	21		
(95% CI)	(9.4, 21.0)	(3.8, 30.1)	(8.2, 16.7)	(9.4, 32.8)		

* 7 patients were inevaluable for response





Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: results from the phase 3 CheckMate 901 trial

<u>Michiel S. van der Heijden</u>,¹ Guru Sonpavde,^{2a} Thomas Powles,³ Andrea Necchi,^{4b} Mauricio Burotto,⁵ Michael Schenker,⁶ Juan Pablo Sade,⁷ Aristotelis Bamias,⁸ Philippe Beuzeboc,⁹ Jens Bedke,^{10c} Jan Oldenburg,¹¹ Yüksel Ürün,¹² Dingwei Ye,¹³ Zhisong He,¹⁴ Begoña P. Valderrama,¹⁵ Yoshihiko Tomita,¹⁶ Jeiry Filian,¹⁷ Daniela Purcea,¹⁸ Federico Nasroulah,¹⁷ Matthew D. Galsky¹⁹


¹Netherlands Cancer Institute, Amsterdam, the Netherlands; ²Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; ³Barts Cancer Institute, Queen Mary University of London, London, UK; ⁴Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; ⁵Bradford Hill Clinical Research Center, Santiago, Chile; ⁶University of Medicine and Pharmacy, Craiova, Romania; ⁷Alexander Fleming Institute, Buenos Aires, Argentina; ⁸National and Kapodistrian University of Athens, ATTIKON University Hospital, Athens, Greece; ⁹Hopital Foch, Suresnes, France; ¹⁰Eberhard Karls University Tübingen, Tübingen, Germany; ¹¹Akershus University Hospital (Ahus), Lørenskog, Norway; ¹²Ankara University, Ankara, Turkey; ¹³Fudan University Shanghai Cancer Center, Shanghai, China; ¹⁴Peking University First Hospital, Beijing, China; ¹⁵Hospital Universitario Virgen del Rocío, Sevilla, Spain; ¹⁶Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; ¹⁷Bristol Myers Squibb, Princeton, NJ, USA; ¹⁸Bristol Myers Squibb, Boudry, Switzerland; ¹⁹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

^aCurrent affiliation is AdventHealth Cancer Institute and University of Central Florida, Orlando, FL, USA. ^bCurrent affiliation is IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Milan, Italy. ^cCurrent affiliation is Klinikum Stuttgart, Katharinenhospital, Stuttgart, Germany.

Presentation number LBA7

Study design

• NIVO + gemcitabine-cisplatin vs gemcitabine-cisplatin in cisplatin-eligible patients^a




Median (range) study follow-up, 33.6 (7.4-62.4) months

Primary endpoints: OS, PFS per BICR **Key secondary endpoints:** OS and PFS by PD-L1 ≥ 1%,^d HRQoL **Key exploratory endpoints:** ORR per BICR, safety

^aFurther CheckMate 901 trial design details are available at https://clinicaltrials.gov/ct2/show/NCT03036098. ^bPatients who discontinued cisplatin could be switched to gemcitabine-carboplatin for the remainder of the platinum doublet cycles (up to 6 in total). ^cA maximum of 24 months from first dose of NIVO administered as part of the NIVO + gemcitabine-cisplatin combination. ^dPD-L1 status was defined by the percentage of positive tumor cell membrane staining in a minimum of 100 tumor cells that could be evaluated with the use of the PD-L1 IHC 28-8 pharmDx immunohistochemical assay (Dako, Santa Clara, CA, USA).


BICR, blinded independent central review; D, day; ECOG PS, Eastern Cooperative Oncology Group performance status; HRQoL, health-related quality of life; ORR, objective response rate; PD-L1, programmed death ligand 1; PFS, progression-free survival; Q×W, every × weeks; R, randomization.

OS (primary endpoint)



Median (range) study follow-up was 33.6 (7.4-62.4) months. OS was estimated in all randomized patients and defined as time from randomization to death from any cause. For patients without documented death, OS was censored on the last date the patient was known to be alive. For randomized patients with no follow-up, OS was censored at randomization.

Objective response outcomes (exploratory endpoints)



Time to and duration of responses


Any objective response ^c	NIVO+GC (n = 175)	GC (n = 131)	
Median TTR (Q1-Q3), months	2.1 (2.0-2.3)	2.1 (2.0-2.2)	
Median DoR (95% CI), months	9.5 (7.6-15.1)	7.3 (5.7-8.9)	

Complete responsed	NIVO+GC (n = 66)	GC (n = 36)
Median TTCR (Q1-Q3), months	2.1 (1.9-2.2)	2.1 (1.9-2.2)
Median DoCR (95% CI), months	37.1 (18.1-NE)	13.2 (7.3-18.4)

aln all randomized patients. ^bThe most common reasons for UE response included death before first tumor assessment, withdrawal of consent, treatment stopped due to toxicity, patient never treated, and receipt of subsequent anticancer therapy before first tumor assessment. ^cBased on patients with an objective response per BICR (PR or CR as BOR). ^dBased on patients with a CR per BICR. BOR, best overall response; CR, complete response; DoCR, duration of complete response; DoR, duration of objective response; NE, not estimable; PD, progressive disease; PR, partial response; Q, quartile; SD, stable disease; TTCR, time to complete response; TTR, time to objective response; UE, unevaluable.

Phase 3 THOR Study: Erdafitinib Versus Chemotherapy of Choice in Patients With Advanced Urothelial Cancer and Selected FGFR Aberrations

Cohort 1



^aMolecular eligibility can be confirmed using either central or local historical *FGFR* test results (Qiagen assay). If a patient was enrolled based on local historical testing, a tissue sample must still be submitted at the time of enrollment for retrospective confirmation (by central lab) of *FGFR* status. Tumors must have ≥ 1 of the following translocations: *FGFR2-BICC1*, *FGFR2-TACC3_V1*, *FGFR3-TACC3_V3*, *FGFR3-BIAP2L1*; or 1 of the following *FGFR3* gene mutations: R248C, S249C, G370C, Y373C.


^bNumber of patients randomized at the time of the interim analysis (data cutoff January 15, 2023).

ECOG PS, Eastern Cooperative Oncology Group performance status; FGFR, fibroblast growth factor receptor; *FGFR3/2alt, FGFR3/2* alterations; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; Q3W, every 3 weeks; tx, treatment; UC, urothelial cancer.




Overall Survival for Erdafitinib Was Superior to Investigator's Choice of Chemotherapy

Objective Response Rate Was Significantly Higher for Erdafitinib Versus Chemotherapy^a



• Median follow-up was 15.9 months

- Median OS was 12.1 months for erdafitinib versus 7.8 months for chemotherapy
- Erdafitinib reduced the risk of death by 36% versus chemotherapy
- HR, 0.64 (95% CI, 0.47-0.88;
 P = 0.005)^a
- Based on these interim analysis results, the IDMC recommended to stop the study, unblind data, and cross over patients from chemotherapy to erdafitinib



Cl, confidence interval; HR, hazard ratio; IDMC, independent data monitoring committee; OS, overall survival. *The significance level for stopping for efficacy was p=0.019, corresponding to a HR of 0.69.

The Safety Profiles Were Consistent With the Known Profiles of Erdafitinib and Chemotherapy (2/2)

Patients with AEs of interest, n (%)	Erdafitinib (n=135)		Chemotherapy (n=112)	
	Any grade	Grade 3-4	Any grade	Grade 3-4
Nail disorders ^a	90 (66.7)	15 (11.1)	6 (5.4)	0
Skin disorders ^b	74 (54.8)	16 (11.9)	14 (12.5)	0
Eye disorders (excluding central serous retinopathy) ^c	57 (42.2)	3 (2.2)	6 (5.4)	0
Central serous retinopathy ^d	23 (17.0)	3 (2.2)	0	0

*Nail disorders: nail bed bleeding, nail discoloration, nail disorder, nail dystrophy, nail ridging, nail toxicity, onycholagia, onychoclasis, onycholysis, paronychia, onychomadesis.
*Skin disorders: blister, dryskin, erythema, hyperkeratosis, palmar epithema, palmar epithema yeathrodysesthesia syndrome, plantar erythema, rash, rash erythematous, rash generalized, rash macular, ras

papular, skin atrophy, skin ekfoliation, skin fissures, skin lesion, skin ulcer, toxic skin eruption, xeroderma. Eve disorders (excluding central serous retinopathy): blephantistic, cataract, scharact subcapsular, conjunctival hemorrhage, conjunctival hyperemia, conjunctival irritation, corneal erosion, corneal infiltrates, dry eye, eye inflammation, eye irritation, eye pin, foreign body sensation in eruses, en gitt blindness, ocular hyperemia, photophobia, vision blurred, visual acuty reduced, visual impairment,

xanthopsis, xerophthalmia, chorioretinitis, conjunctivitis, ulcerative keratitis. "Central serous etionpathy: retinand leachment, vitrous detachment, vitrous detachment, retinal pigment epithelium, macular detachment, serous retinal detachment, subretinal fluid, retinal thickening, chorioretinitis, serous retinopathy, maculopathy, choroidal effusion. AE, adverse event.



THOR Cohort 1: Conclusions

- Erdafitinib significantly extended OS in patients with advanced/mUC with *FGFRalt* after prior treatment with anti–PD-(L)1, with a median OS of 1 year
- Erdafitinib provided a 36% reduction in risk of death compared to chemotherapy
- The OS benefit of erdafitinib was consistent across clinically relevant subgroups
- Erdafitinib provided significantly longer PFS and greater ORR versus chemotherapy
- Erdafitinib safety profile was consistent with the BLC2001 study^{1,2}
- The phase 3 THOR study supports the clinical efficacy of erdafitinib as the standard of care option for patients with mUC with *FGFRalt* after anti–PD-(L)1 treatment
- The OS benefit of erdafitinib in patients with mUC with *FGFRalt* supports molecular testing for *FGFRalt* in all patients with mUC

FGFRalt, FGFRalterations; mUC, metastatic urothelial carcinoma; ORR, overall response rate; OS, overall survival; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PFS, progression-free survival. 1. Loriot Y, et al. N Engl / Med. 2019;381:338-348; 2. Siefker-Radtke AO, et al. Lancet Oncol. 2022;23:248-258.



Her2 ADC ©Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

Funda Meric-Bernstam, MD¹ (D); Vicky Makker, MD^{2,3} (D); Ana Oaknin, MD⁴ (D); Do-Youn Oh, MD⁵ (D); Susana Banerjee, PhD⁶ (D); Antonio González-Martín, MD⁷ (D); Kyung Hae Jung, MD⁸ (D); Iwona Ługowska, MD⁹; Luis Manso, MD¹⁰ (D); Aránzazu Manzano, MD¹¹; Bohuslav Melichar, MD¹²; Salvatore Siena, MD¹³ (D); Daniil Stroyakovskiy, MD¹⁴ (D); Anitra Fielding, MBChB¹⁵; Yan Ma, MSc¹⁶; Soham Puvvada, MD¹⁵; Norah Shire, PhD¹⁵; and Jung-Yun Lee, MD¹⁷ (D)




TABLE 2. Incidence of Drug-Related Adverse Events

Adverse Event	Bladder Cancer $(n = 41)$	
Drug-related adverse events, No. (%)	38 (92.7)	
Grade ≥3	17 (41.5)	
Serious adverse events	4 (9.8)	
Leading to discontinuation	4 (9.8)	
Leading to dose modification ^a	15 (36.6)	
Associated with death	1 (2.4)	
Most common drug-related adverse events (>10% of total patients), No.		
Nausea	21 (51.2)	
Anemia	12 (29.3)	
Diarrhea	13 (31.7)	
Fatigue	11 (26.8)	
Vomiting	6 (14.6)	
Neutropenia	11 (26.8)	
Decreased appetite	8 (19.5)	
Asthenia	3 (7.3)	
Alopecia	5 (12.2)	
Thrombocytopenia	6 (14.6)	

J Clin Oncol 42:47-58 © 2023 by American Society of Clinical Oncology

Her2 ADC •Efficacy and Safety of TI With HER2-Expressing S the DESTINY-PanTumor(

Funda Meric-Bernstam, MD¹ (1); Vicky Makker, MD² (1); Antonio González-Martin, MD⁷ (1); Kyung Hae Jung, MD⁸ (1) Bohuslav Melichar, MD¹²; Salvatore Siena, MD¹³ (1); Daniil Sti Norah Shire, PhD¹⁵; and Jung-Yun Lee, MD¹⁷ (1)

DOI https://doi.org/10.1200/JC0.23.02005




Table 2. HER2	Status by	UC Stage ^a :	Assay Results	5
---------------	-----------	-------------------------	----------------------	---

		N (row %)		
Stage	N	HER2+	HER2-low	HER2-zero
Stage I	7	1 (14)	0	6 (86)
Stage II	133	17 (13)	46 (35)	70 (53)
Stage III	192	37 (19)	50 (26)	102 (55)
Stage IV	30	2 (7)	7 (23)	21 (70)
All	362	57 (16)	103 (28)	202 (56)

a Stage information as supplied by the tissue vendor. Staging may have been based on clinical information or on tissue samples different from those included in the current study

Table 3. Summary of HER2 Status

HER2 Status	N	Percentage of samples (95% CI)
HER2+ and HER2-low	160	44.2% (39.2%–49.3%)
HER2+/overexpression	57	15.7% 12.4%–19.9%)
HER2-low	103	28.5% (24.1%-33.3%)
HER2-zero	202	55.8% (50.7%-60.8%)

lated Adverse Events

	Bladder Cancer $(n = 41)$
b)	38 (92.7)
	17 (41 5)
	4 (9.8)
	4 (9.8)
	15 (36.6)
	1 (2.4)
events (>10% of total patients), No	
	21 (51.2)
	12 (29.3)
	13 (31.7)
	11 (26.8)
	6 (14.6)
	11 (26.8)
	8 (19.5)
	3 (7.3)
	5 (12.2)
	6 (14.6)

Koshkin et al, ASCO GU 2023, J Clin Oncol 41, 2023 (suppl 6; abstr 556)

Systemic Therapy in Urothelial Carcinoma

Sarmad Sadeghi, MD, PhD Department of Medicine Institute of Urology University of Southern California August 24, 2024

For more information contact me at <u>Sarmad.Sadeghi@med.usc.edu</u> or call 216-533-4045"

